Prognostic Factors Identified for Retroperitoneal Leiomyosarcoma Survival

Strategic Insights -

Retroperitoneal leiomyosarcoma, a rare and aggressive type of cancer, has been found to have prognostic factors that can predict overall survival after initial resection and subsequent surgery for recurrence. A recent study from Fudan University in Shanghai, People's Republic of China, analyzed 227 patients who underwent surgery for retroperitoneal leiomyosarcoma from January 2002 to December 2022. The researchers identified maximum tumor diameter, Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade, platelet count, and neutrophil/lymphocyte ratio as independent risk factors for overall survival in primary retroperitoneal leiomyosarcoma patients. In recurrent retroperitoneal leiomyosarcoma patients, neutrophil/lymphocyte ratio and disease-free interval were significant for overall survival.

Key Takeaways:

  • The study analyzed 227 retroperitoneal leiomyosarcoma patients who underwent surgery from January 2002 to December 2022.
  • Maximum tumor diameter, FNCLCC grade, platelet count, and neutrophil/lymphocyte ratio are independent risk factors for overall survival in primary retroperitoneal leiomyosarcoma patients.
  • Neutrophil/lymphocyte ratio and disease-free interval are significant for overall survival in recurrent retroperitoneal leiomyosarcoma patients.
  • Long-term survival is achievable in selected recurrent retroperitoneal leiomyosarcoma patients post-surgery.
  • The findings may aid in risk stratification and treatment decisions for retroperitoneal leiomyosarcoma patients.

Statistics:

  • 227 patients were analyzed in the study.
  • 61.4% of primary retroperitoneal leiomyosarcoma patients and 33% of recurrent retroperitoneal leiomyosarcoma patients were censored at the last follow-up.
  • Median overall survival was 62 months for primary retroperitoneal leiomyosarcoma and 33 months for recurrent retroperitoneal leiomyosarcoma.
  • The median follow-up time was 42 months (IQR 21-95 months) for primary retroperitoneal leiomyosarcoma, 40 months (IQR 24-73 months) for recurrent retroperitoneal leiomyosarcoma, and 43 months (IQR 21-83 months) for the overall cohort.

Sources:

  • The prognosis factors landscape of surgical management of retroperitoneal leiomyosarcoma: A retrospective multicenter study (The American Journal of Surgery, 2025;250:116647)
  • NewsRx. New Leiomyosarcoma Findings Reported from Fudan University (The prognosis factors landscape of surgical management of retroperitoneal leiomyosarcoma: A retrospective multicenter study). Health & Medicine Week. October 31, 2025; p 1000.